267 related articles for article (PubMed ID: 35734820)
1. Elastic Nanovaccine Enhances Dendritic Cell-Mediated Tumor Immunotherapy.
Li Q; Teng Z; Tao J; Shi W; Yang G; Zhang Y; Su X; Chen L; Xiu W; Yuwen L; Dong H; Mou Y
Small; 2022 Aug; 18(32):e2201108. PubMed ID: 35734820
[TBL] [Abstract][Full Text] [Related]
2. Facile preparation of a metal-phenolic network-based lymph node targeting nanovaccine for antitumor immunotherapy.
Su Q; Liu Z; Du R; Chen X; Chen L; Fu Z; Luo X; Yang Y; Shi X
Acta Biomater; 2023 Mar; 158():510-524. PubMed ID: 36603733
[TBL] [Abstract][Full Text] [Related]
3. Engineering ApoE3-incorporated biomimetic nanoparticle for efficient vaccine delivery to dendritic cells via macropinocytosis to enhance cancer immunotherapy.
Zhou S; Huang Y; Chen Y; Liu S; Xu M; Jiang T; Song Q; Jiang G; Gu X; Gao X; Chen J
Biomaterials; 2020 Mar; 235():119795. PubMed ID: 32014739
[TBL] [Abstract][Full Text] [Related]
4. Polyanhydride Nanoparticles Induce Low Inflammatory Dendritic Cell Activation Resulting in CD8
Darling R; Senapati S; Christiansen J; Liu L; Ramer-Tait AE; Narasimhan B; Wannemuehler M
Int J Nanomedicine; 2020; 15():6579-6592. PubMed ID: 32982219
[TBL] [Abstract][Full Text] [Related]
5. Nanovaccine-Based Strategies to Overcome Challenges in the Whole Vaccination Cascade for Tumor Immunotherapy.
Qin L; Zhang H; Zhou Y; Umeshappa CS; Gao H
Small; 2021 Jul; 17(28):e2006000. PubMed ID: 33768693
[TBL] [Abstract][Full Text] [Related]
6. Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy.
Jiang M; Zhao L; Cui X; Wu X; Zhang Y; Guan X; Ma J; Zhang W
J Adv Res; 2022 Jan; 35():49-60. PubMed ID: 35003793
[TBL] [Abstract][Full Text] [Related]
7. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
[TBL] [Abstract][Full Text] [Related]
8. Highly enhanced cancer immunotherapy by combining nanovaccine with hyaluronidase.
Guan X; Chen J; Hu Y; Lin L; Sun P; Tian H; Chen X
Biomaterials; 2018 Jul; 171():198-206. PubMed ID: 29698869
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell hybrid nanovaccine for mild heat inspired cancer immunotherapy.
Shi C; Jian C; Wang L; Gao C; Yang T; Fu Z; Wu T
J Nanobiotechnology; 2023 Sep; 21(1):347. PubMed ID: 37752555
[TBL] [Abstract][Full Text] [Related]
10. Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy.
Song H; Su Q; Shi W; Huang P; Zhang C; Zhang C; Liu Q; Wang W
Acta Biomater; 2022 Mar; 141():398-407. PubMed ID: 35007785
[TBL] [Abstract][Full Text] [Related]
11. Vaccination of TLR7/8 Agonist-Conjugated Antigen Nanoparticles for Cancer Immunotherapy.
Wang N; Zhang G; Zhang P; Zhao K; Tian Y; Cui J
Adv Healthc Mater; 2023 Sep; 12(22):e2300249. PubMed ID: 37016572
[TBL] [Abstract][Full Text] [Related]
12. Minimalist Nanovaccine with Optimized Amphiphilic Copolymers for Cancer Immunotherapy.
Niu L; Miao Y; Cao Z; Wei T; Zhu J; Li M; Bai B; Chen L; Liu N; Pan F; Zhu J; Wang C; Yang Y; Chen Q
ACS Nano; 2024 Jan; 18(4):3349-3361. PubMed ID: 38230639
[TBL] [Abstract][Full Text] [Related]
13. Nanovaccine Incorporated with Hydroxychloroquine Enhances Antigen Cross-Presentation and Promotes Antitumor Immune Responses.
Liu J; Liu X; Han Y; Zhang J; Liu D; Ma G; Li C; Liu L; Kong D
ACS Appl Mater Interfaces; 2018 Sep; 10(37):30983-30993. PubMed ID: 30136844
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy.
Jiang X; Wang J; Zheng X; Liu Z; Zhang X; Li Y; Wilhelm J; Cao J; Huang G; Zhang J; Sumer B; Lea J; Lu Z; Gao J; Luo M
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35623658
[TBL] [Abstract][Full Text] [Related]
15. Mimetic Heat Shock Protein Mediated Immune Process to Enhance Cancer Immunotherapy.
Li X; Cai X; Zhang Z; Ding Y; Ma R; Huang F; Liu Y; Liu J; Shi L
Nano Lett; 2020 Jun; 20(6):4454-4463. PubMed ID: 32401534
[TBL] [Abstract][Full Text] [Related]
16. Manganese oxide-constructed multifunctional biomimetic nanovaccine for robust tumor-specific T cell priming and chemodynamic therapy.
Li T; Chen G; Lin L; Li B; Wang X; Chen Y; Huang W; Cai M; Xiao Z; Shuai X; Zhu K
Biomaterials; 2024 Sep; 309():122626. PubMed ID: 38795524
[TBL] [Abstract][Full Text] [Related]
17. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
[TBL] [Abstract][Full Text] [Related]
18. A biotin-avidin-system-based virus-mimicking nanovaccine for tumor immunotherapy.
Lu Z; Zhang Y; Wang Y; Tan GH; Huang FY; Cao R; He N; Zhang L
J Control Release; 2021 Apr; 332():245-259. PubMed ID: 33647430
[TBL] [Abstract][Full Text] [Related]
19. Endogenous/Exogenous Nanovaccines Synergistically Enhance Dendritic Cell-Mediated Tumor Immunotherapy.
Zhang Y; Li Q; Ding M; Xiu W; Shan J; Yuwen L; Yang D; Song X; Yang G; Su X; Mou Y; Teng Z; Dong H
Adv Healthc Mater; 2023 Jul; 12(17):e2203028. PubMed ID: 36807733
[TBL] [Abstract][Full Text] [Related]
20. Liposomes-coated gold nanocages with antigens and adjuvants targeted delivery to dendritic cells for enhancing antitumor immune response.
Liang R; Xie J; Li J; Wang K; Liu L; Gao Y; Hussain M; Shen G; Zhu J; Tao J
Biomaterials; 2017 Dec; 149():41-50. PubMed ID: 28992509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]